Evans John M. 的 Form 4/A 修正申報
修正Beam Therapeutics Inc.（BEAM），2025/4/2 申報
- 申報編號
- 0000950170-25-049297
- 申報時間
- 2025/4/2
- 交易日
- 2025/1/30
- 申報延遲
- 62 天
- 10b5-1 計畫
- 有勾選
- 原始申報日
- 2025/2/3
這份申報列了 1 筆非衍生性交易、1 筆衍生性交易。沿用原件裡沒有重述的 3 筆交易。公開市場賣出合計 $80.3 萬。交易後 62 天申報。
這份修正申報重述了 0000950170-25-012304（2025/2/3 申報）的一部分，沒有重述的交易仍然有效，列在下面。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Evans John M.CIK 0001786304 | 董事、高階主管（執行長） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/1/30 | Common Stock | M行使選擇權取得 | +30,000 | $0.67 | +$20,100 | 968,659 | 直接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/1/30 | Common Stock | M行使選擇權處分 | −30,000 | $0.00 | $0 | 69,336 | 直接 |
沿用原件的交易
這份修正申報只重述了原件的一部分。原件其他的交易仍然有效，網站的交易表把它們算在這份修正申報底下。
來自 0000950170-25-012304（2025/2/3 申報）。
非衍生性證券（表 I）
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/1/30 | Common Stock | S賣出處分 | −29,800 | $26.75F2 | −$797,150 | 908,859 | 直接 | |
| 2025/1/30 | Common Stock | S賣出處分 | −200 | $27.28 | −$5,456 | 908,659 | 直接 |
衍生性證券（表 II）
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/1/31 | Common Stock | A公司授予取得 | +155,000 | $0.00 | $0 | 155,000 | 直接 |
原件的附註
這幾筆交易的價格在原件上引用的附註。
- F2
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $26.26 to $27.21 inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
表 I 有 1 筆交易的價格引用這則附註。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
On February 3, 2025, the Reporting Person filed a Form 4 (the "Original Form 4") that, among other things, reported the sale of shares of common stock pursuant to a Rule 10b5-1 trading plan. The Original Form 4 inadvertently failed to disclose the exercise of derivative securities that occurred pursuant to the same Rule 10b5-1 trading plan, which occurred immediately prior to such sale. Accordingly, this Form 4/A is being filed to disclose the omitted transaction. Immediately following the transaction reported herein, the Reporting Person directly beneficially owned 968,659 shares of common stock of Beam Therapeutics Inc.
- F2
(Continued from footnote 1) ("BEAM"), and accordingly, all disclosures of the amount of securities directly beneficially owned by the Reporting Person subsequent to the transaction reported herein and prior to the filing of this Form 4/A, including with respect to the transactions reported in the Original Form 4, should be deemed to be adjusted accordingly. As of the date the filing of this Form 4/A, the Reporting Person directly beneficially owns 938,659 shares of common stock of BEAM.
- F3
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2024.
- F4
On May 8, 2018, the Reporting Person was granted an option to purchase shares of common stock, which vested as to 99,336 shares upon the achievement of a closing hurdle following BEAM's initial public offering (which closing price hurdle was achieved) (the "Price Condition"). The portion of the award subject to the Price Condition vested in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.